Oral IIa Inhibitors
Direct oral factor IIa inhibitors represent a new class of anticoagulants for the prevention and treatment of venous and selected arterial thomboembolisms. Dabigatran etexilate is the most studied and promising…
Direct oral factor IIa inhibitors represent a new class of anticoagulants for the prevention and treatment of venous and selected arterial thomboembolisms. Dabigatran etexilate is the most studied and promising…
Several new oral drugs that selectively and directly inhibit factor Xa seem promising alternatives to existing antithrombotic drugs. These drugs have a convenient route of administration, can be given in…
Although warfarin has been the mainstay of oral anticoagulation therapy for decades, evidence-based methods for improving the quality of warfarin therapy remain underused. The arrival of new anticoagulants that do…
Venous thromboembolic events are common in patients with malignancy, producing both morbidity and mortality. Although the underlying mechanisms by which cancer might promote a procoagulant state are multifaceted and incompletely…
VTE can be considered as a multicausal disease involving various inherited and acquired prothrombotic conditions. Although greater emphasis has classically been given to traditional thrombophilic risk factors, there is increasing…
Given the known increased risk of venous thromboembolism (VTE) associated with both oral contraceptive (OC) use and hormone replacement therapy (HRT), it is important to address questions about the prevention…
Antiphospholipid syndrome (APS) is a systemic disease that causes venous and arterial thrombosis in virtually any organ and is responsible for fetal losses and pregnancy disorders. Previously, APS was thought…
Pulmonary embolism (PE) is the most dangerous complication of venous thrombosis. Objectively confirmed PE is a potentially life-threatening complication of critical illness. In medical-surgical critically ill patients, signs and symptoms…